Murex granted approval for five latex agglutination tests:
This article was originally published in Clinica
Executive Summary
International Murex has launched five latex agglutination tests in the US following FDA approval. The kits detect antibodies to infectious mononucleosis, group A streptococcus, rheumatoid arthritis and C-reactive protein. The tests will be marketed to clinical reference and hospital laboratories. The company estimates the collective US market for these tests at around $20 million. The tests provide results in between two and ten minutes, says Murex.